Trials / Completed
CompletedNCT04825834
DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,992 (actual)
- Sponsor
- Delfi Diagnostics Inc. · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study, DELFI-L101, is to train and test classifiers for lung cancer detection using the DELFI assay and other biomarker and clinical features.
Detailed description
Subjects will be enrolled into the DELFI-L101 study after informed consent and eligibility is confirmed. At enrollment, subjects will have blood specimens collected (\~40 mL) and 12 months post-enrollment their medical records will be reviewed.
Conditions
- Lung Cancer
- Head and Neck Cancer
- Esophageal Cancer
- Bladder Cancer
- Kidney Cancer
- Stomach Cancer
- Colorectal Cancer
- Pancreas Cancer
- Liver Cancer
- Skin Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Blood Sample Collection | Subjects enrolled in the DELFI-L101 will have blood specimens collected (\~40 mL) at enrollment. |
Timeline
- Start date
- 2021-03-22
- Primary completion
- 2025-07-15
- Completion
- 2025-07-15
- First posted
- 2021-04-01
- Last updated
- 2025-08-08
Locations
57 sites across 2 countries: United States, Puerto Rico
Source: ClinicalTrials.gov record NCT04825834. Inclusion in this directory is not an endorsement.